Abstract: The invention relates to compounds of formula I and to pharmaceutically acceptable salts, prodrugs, solvates or hydrates thereof. This invention also relates to a method of using such compounds in the treatment of hyperproliferative diseases and autoimmune diseases in mammals, especially humans, and to pharmaceutical compositions containing such compounds.
Type:
Application
Filed:
November 7, 2008
Publication date:
September 10, 2009
Inventors:
Samit K. Bhattacharya, Matthew F. Brown, Peter H. Dorff, Susan D. LaGreca, John W. Mickelson, Joseph A. Cornicelli, David L. Brown, Rex Jennings, John K. Walker, Rita Huff, Joseph W. Strohbach, Robert J. Maguire
Abstract: The present invention relates to compounds of the formula I and the pharmaceutically acceptable forms thereof; wherein X, Y, a, b, c, d, R1, R2, R3, R4 and R5 are as defined herein. Moreover, the present invention is also directed at pharmaceutical compositions comprising a compound of the formula I and a pharmaceutically acceptable carrier. Furthermore, the present invention is directed at methods of using the herein described compounds and compositions for treating or preventing a disorder or condition that can be treated or prevented by antagonizing the CCR1 receptor in a mammal.
Type:
Grant
Filed:
October 18, 2002
Date of Patent:
August 29, 2006
Inventors:
Laura C. Blumberg, Matthew F. Brown, Matthew M. Hayward, Gregory D. Lundquist, Christopher S. Poss, Andrei Shavnya
Abstract: The invention relates to compounds of formula I and to pharmaceutically acceptable salts, prodrugs, solvates or hydrates thereof. This invention also relates to a method of using such compounds in the treatment of hyperproliferative diseases and autoimmune diseases in mammals, especially humans, and to pharmaceutical compositions containing such compounds.
Type:
Application
Filed:
May 13, 2010
Publication date:
September 16, 2010
Inventors:
Samit K. Bhattacharya, Matthew F. Brown, Peter H. Dorff, Susan D. LaGreca, John W. Mickelson, Joseph A. Cornicelli, David L. Brown, Jennings Rex, John K. Walker, Rita Huff, Joseph W. Strohbach, Robert J. Maguire
Abstract: Provided are imaging agents comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof, and methods of their use.
Type:
Application
Filed:
October 26, 2018
Publication date:
June 6, 2019
Inventors:
Celia Dominguez, John Wityak, Jonathan Bard, Christopher John Brown, Michael Edward Prime, Peter David Johnson, Thomas Martin Krulle, Daniel Clark-Frew, Duane Higgins, Matthew Robert Mills, Richard Waldron Marston, Samuel Coe, Samantha Brown, Sarah Hayes
Abstract: Provided are imaging agents comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof, and methods of their use.
Type:
Application
Filed:
August 6, 2020
Publication date:
March 4, 2021
Inventors:
Celia Dominguez, John Wityak, Jonathan Bard, Christopher John Brown, Michael Edward Prime, Peter David Johnson, Thomas Martin Krulle, Daniel Clark-Frew, Duane Higgins, Matthew Robert Mills, Richard Waldron Marston, Samuel Coe, Samantha Brown, Sarah Hayes
Abstract: Provided are imaging agents comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof, and methods of their use.
Type:
Grant
Filed:
October 26, 2018
Date of Patent:
September 8, 2020
Assignee:
CHDI Foundation, Inc.
Inventors:
Celia Dominguez, John Wityak, Jonathan Bard, Christopher John Brown, Michael Edward Prime, Peter David Johnson, Thomas Martin Krulle, Daniel Clark-Frew, Duane Higgins, Matthew Robert Mills, Richard Waldron Marston, Samuel Coe, Samantha Brown, Sarah Hayes
Abstract: Provided are imaging agents comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof, and methods of their use.
Type:
Grant
Filed:
August 6, 2020
Date of Patent:
May 31, 2022
Assignee:
CHDI FOUNDATION, INC.
Inventors:
Celia Dominguez, John Wityak, Jonathan Bard, Christopher John Brown, Michael Edward Prime, Peter David Johnson, Thomas Martin Krulle, Daniel Clark-Frew, Duane Higgins, Matthew Robert Mills, Richard Waldron Marston, Samuel Coe, Samantha Brown, Sarah Hayes
Abstract: Provided are imaging agents comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof, and methods of their use
Type:
Grant
Filed:
August 26, 2016
Date of Patent:
November 27, 2018
Assignee:
CHDI Foundation, Inc.
Inventors:
Celia Dominguez, John Wityak, Jonathan Bard, Christopher John Brown, Michael Edward Prime, Peter David Johnson, Thomas Martin Krulle, Daniel Clark-Frew, Duane Higgins, Matthew Robert Mills, Richard Waldron Marston, Samuel Coe, Samantha Brown, Sarah Hayes
Abstract: Thienopyridone compounds of formula (I): or a salt thereof, pharmaceutical compositions containing such compounds and their use in therapy, in particular in the treatment of diseases or conditions for which a bromodomain inhibitor is indicated.
Type:
Application
Filed:
November 12, 2013
Publication date:
October 13, 2016
Inventors:
Dominique AMANS, Paul BAMBOROUGH, Rino Antonio BIT, John Alexander BROWN, Matthew CAMPBELL, Matthew John LINDON, Tracy Jane SHIPLEY, Natalie Hope THEODOULOU, Christopher Roland WELLAWAY, Susan Marie WESTAWAY
Abstract: The present invention provides, in part, compounds of Formula I: or an N-oxide thereof, or a pharmaceutically acceptable salt of the compound or the N-oxide, wherein: R1, R2, L, A, and E are as described herein; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds, N-oxides, or salts, and their uses for treating M4-mediated (or M4-associated) disorders including, e.g., Alzheimer's Disease, schizophrenia (e.g., its cognitive and negative symptoms), pain, addiction, and a sleep disorder.
Type:
Application
Filed:
February 21, 2023
Publication date:
June 22, 2023
Inventors:
Lei Zhang, Christopher Ryan Butler, Elizabeth Mary Beck, Michael Aaron Brodney, Matthew Frank Brown, Laura Ann McAllister, Erik Alphie LaChapelle, Adam Matthew Gilbert
Abstract: The present invention provides, in part, compounds of Formula I: or an N-oxide thereof, or a pharmaceutically acceptable salt of the compound or the N-oxide, wherein: R1, R2, L, A, and E are as described herein; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds, N-oxides, or salts, and their uses for treating M4-mediated (or M4-associated) disorders including, e.g., Alzheimer's Disease, schizophrenia (e.g., its cognitive and negative symptoms), pain, addiction, and a sleep disorder.
Type:
Application
Filed:
June 29, 2017
Publication date:
January 4, 2018
Applicant:
Pfizer Inc.
Inventors:
Lei Zhang, Christopher Ryan Butler, Elizabeth Mary Beck, Michael Aaron Brodney, Matthew Frank Brown, Laura Ann McAllister, Erik Alphie LaChapelle, Adam Matthew Gilbert
Abstract: The present invention provides, in part, compounds of Formula I: or an N-oxide thereof, or a pharmaceutically acceptable salt of the compound or the N-oxide, wherein: R1, R2, L, A, and E are as described herein; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds, N-oxides, or salts, and their uses for treating M4-mediated (or M4-associated) disorders including, e.g., Alzheimer's Disease, schizophrenia (e.g., its cognitive and negative symptoms), pain, addiction, and a sleep disorder.
Type:
Application
Filed:
February 21, 2020
Publication date:
July 2, 2020
Inventors:
Lei Zhang, Christopher Ryan Butler, Elizabeth Mary Beck, Michael Aaron Brodney, Matthew Frank Brown, Laura Ann McAllister, Erik Alphie LaChapelle, Adam Matthew Gilbert
Abstract: The present invention provides, in part, compounds of Formula I: or an N-oxide thereof, or a pharmaceutically acceptable salt of the compound or the N-oxide, wherein: R1, R2, L, A, and E are as described herein; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds, N-oxides, or salts, and their uses for treating M4-mediated (or M4-associated) disorders including, e.g., Alzheimer's Disease, schizophrenia (e.g., its cognitive and negative symptoms), pain, addiction, and a sleep disorder.
Type:
Application
Filed:
June 1, 2021
Publication date:
October 7, 2021
Inventors:
Lei Zhang, Christopher Ryan Butler, Elizabeth Mary Beck, Michael Aaron Brodney, Matthew Frank Brown, Laura Ann McAllister, Erik Alphie LaChapelle, Adam Matthew Gilbert
Abstract: The present invention provides, in part, compounds of Formula I, or an N-oxide thereof, or a pharmaceutically acceptable salt of the compound or the N-oxide, wherein: (R1)a, (R2)b, (R3)c, L, A, and E are as described herein; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds, N-oxides, or salts, and their uses for treating M4-mediated (or M4-associated) disorders including, e.g., Alzheimer's Disease, schizophrenia (e.g., its cognitive and negative symptoms), pain, addiction, and a sleep disorder.
Type:
Application
Filed:
June 14, 2018
Publication date:
August 20, 2020
Inventors:
Elizabeth Mary Beck, Michael Aaron Brodney, Matthew Frank Brown, Christopher Ryan Butler, Adam Matthew Gilbert, Erik Alphie Lachapelle, Laura Ann McAllister, Daniel Paul Uccello, Lei Zhang
Abstract: The present invention provides, in part, compounds of Formula I: or an N-oxide thereof, or a pharmaceutically acceptable salt of the compound or the N-oxide, wherein: R1, R2, L, A, and E are as described herein; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds, N-oxides, or salts, and their uses for treating M4-mediated (or M4-associated) disorders including, e.g., Alzheimer's Disease, schizophrenia (e.g., its cognitive and negative symptoms), pain, addiction, and a sleep disorder.
Type:
Grant
Filed:
June 1, 2021
Date of Patent:
February 20, 2024
Assignee:
PFIZER INC.
Inventors:
Lei Zhang, Christopher Ryan Butler, Elizabeth Mary Beck, Michael Aaron Brodney, Matthew Frank Brown, Laura Ann McAllister, Erik Alphie LaChapelle, Adam Matthew Gilbert
Abstract: The present invention provides, in part, compounds of Formula I: or an N-oxide thereof, or a pharmaceutically acceptable salt of the compound or the N-oxide, wherein: R1, R2, L, A, and E are as described herein; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds, N-oxides, or salts, and their uses for treating M4-mediated (or M4-associated) disorders including, e.g., Alzheimer's Disease, schizophrenia (e.g., its cognitive and negative symptoms), pain, addiction, and a sleep disorder.
Type:
Grant
Filed:
June 29, 2017
Date of Patent:
March 31, 2020
Assignee:
Pfizer Inc.
Inventors:
Lei Zhang, Christopher Ryan Butler, Elizabeth Mary Beck, Michael Aaron Brodney, Matthew Frank Brown, Laura Ann McAllister, Erik Alphie LaChapelle, Adam Matthew Gilbert
Abstract: The present invention provides, in part, compounds of Formula I, or an N-oxide thereof, or a pharmaceutically acceptable salt of the compound or the N-oxide, wherein: (R1)a, (R2)b, (R3)c, L, A, and E are as described herein; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds, N-oxides, or salts, and their uses for treating M4-mediated (or M4-associated) disorders including, e.g., Alzheimer's Disease, schizophrenia (e.g., its cognitive and negative symptoms), pain, addiction, and a sleep disorder.
Type:
Grant
Filed:
June 14, 2018
Date of Patent:
December 14, 2021
Assignee:
PFIZER INC.
Inventors:
Elizabeth Mary Beck, Michael Aaron Brodney, Matthew Frank Brown, Christopher Ryan Butler, Adam Matthew Gilbert, Erik Alphie Lachapelle, Laura Ann McAllister, Daniel Paul Uccello, Lei Zhang
Abstract: Thienopyridone compounds of formula (I): or a salt thereof, pharmaceutical compositions containing such compounds and their use in therapy, in particular in the treatment of diseases or conditions for which a bromodomain inhibitor is indicated.
Type:
Grant
Filed:
November 12, 2013
Date of Patent:
May 30, 2017
Assignee:
GlaxoSmithKline LLC
Inventors:
Dominique Amans, Paul Bamborough, Rino Antonio Bit, John Alexander Brown, Matthew Campbell, Matthew John Lindon, Tracy Jane Shipley, Natalie Hope Theodoulou, Christopher Roland Wellaway, Susan Marie Westaway
Abstract: Embodiments are directed towards a use of a supported gas-phase biphenylphenol polymerization catalyst to make a polymer via a gas-phase polymerization process, wherein the supported gas-phase biphenylphenol polymerization catalyst is made from a gas-phase biphenylphenol polymerization precatalyst of Formula I.
Type:
Application
Filed:
December 17, 2020
Publication date:
March 30, 2023
Applicant:
Dow Global Technologies LLC
Inventors:
Angela I. Padilla-Acevedo, Andrew J. Young, Roger L. Kuhlman, Susan Brown, Matthew E. Belowich, David R. Neithamer, Jerzy Klosin, David M. Pearson, Leslie E. O'Leary, Joseph F. DeWilde
Abstract: Embodiments are directed towards the use of a supported biphenylphenol polymerization catalyst made from a biphenylphenol polymerization precatalyst of Formula I via a gas-phase or slurry-phase polymerization process under gas-phase or slurry-phase polymerization conditions to make a polymer.
Type:
Application
Filed:
November 4, 2020
Publication date:
December 22, 2022
Applicant:
Dow Global Technologies LLC
Inventors:
Angela I. Padilla-Acevedo, Andrew J. Young, Roger L. Kuhlman, Ruth Figueroa, Susan Brown, Matthew E. Belowich, David R. Neithamer, Jerzy Klosin, David M. Pearson, Mari S. Rosen, Bethany M. Neilson, Johnathan E. DeLorbe, Leslie E. O'Leary